Xiaoli Shan

516 total citations
22 papers, 377 citations indexed

About

Xiaoli Shan is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Xiaoli Shan has authored 22 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Cardiology and Cardiovascular Medicine and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Xiaoli Shan's work include Cardiac Fibrosis and Remodeling (7 papers), Signaling Pathways in Disease (6 papers) and Cardiac Ischemia and Reperfusion (4 papers). Xiaoli Shan is often cited by papers focused on Cardiac Fibrosis and Remodeling (7 papers), Signaling Pathways in Disease (6 papers) and Cardiac Ischemia and Reperfusion (4 papers). Xiaoli Shan collaborates with scholars based in China, United Kingdom and Portugal. Xiaoli Shan's co-authors include Pei Zhao, Rong Lü, Wei Guo, Chen Zhang, Ming Xu, Huihua Chen, Jing Tian, Han Li, Shui-jin Shao and Ke Ning and has published in prestigious journals such as Biochemical and Biophysical Research Communications, International Journal of Molecular Sciences and Journal of Ethnopharmacology.

In The Last Decade

Xiaoli Shan

21 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoli Shan China 10 206 97 50 49 38 22 377
Meizhu Wu China 13 268 1.3× 81 0.8× 32 0.6× 32 0.7× 29 0.8× 43 452
Ningtian Zhou China 11 219 1.1× 91 0.9× 56 1.1× 30 0.6× 45 1.2× 20 388
V. Vijaya Padma India 14 233 1.1× 91 0.9× 39 0.8× 25 0.5× 53 1.4× 21 478
Wei‐Yin Wu China 13 241 1.2× 103 1.1× 39 0.8× 29 0.6× 56 1.5× 24 452
Hongchen Lin China 6 147 0.7× 58 0.6× 78 1.6× 50 1.0× 27 0.7× 7 359
Guoqiang Fu China 12 234 1.1× 96 1.0× 46 0.9× 27 0.6× 26 0.7× 23 507
Qiong Lai China 12 232 1.1× 60 0.6× 30 0.6× 41 0.8× 56 1.5× 19 389
Mingtai Chen China 10 196 1.0× 66 0.7× 37 0.7× 62 1.3× 107 2.8× 44 426

Countries citing papers authored by Xiaoli Shan

Since Specialization
Citations

This map shows the geographic impact of Xiaoli Shan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoli Shan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoli Shan more than expected).

Fields of papers citing papers by Xiaoli Shan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoli Shan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoli Shan. The network helps show where Xiaoli Shan may publish in the future.

Co-authorship network of co-authors of Xiaoli Shan

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoli Shan. A scholar is included among the top collaborators of Xiaoli Shan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoli Shan. Xiaoli Shan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jin, Wenyi, Xiaoli Shan, Yubiao Zhang, et al.. (2025). Optimizing mitochondria function in immune cells: implications for cancer immunotherapy. Trends in cancer. 11(12). 1170–1184. 1 indexed citations
2.
Li, Rongshan, Xiaoli Shan, Pei Zhao, et al.. (2025). Stachydrine hydrochloride reduces NOX2 activity to suppress oxidative stress levels to improve cardiac insufficiency. Phytomedicine. 140. 156621–156621. 2 indexed citations
3.
Shan, Xiaoli, Pei Zhao, Huihua Chen, et al.. (2024). Ginsenoside Rb1 ameliorates lipotoxicity-induced myocardial injury in diabetes mellitus by regulating Mfn2. European Journal of Pharmacology. 974. 176609–176609. 9 indexed citations
4.
5.
Chen, Yuwen, Jingzhi Chen, Wei Guo, et al.. (2024). Stachydrine hydrochloride protects the ischemic heart by ameliorating endoplasmic reticulum stress through a SERCA2a dependent way and maintaining intracellular Ca2+ homeostasis. European Journal of Pharmacology. 973. 176585–176585. 7 indexed citations
6.
Lu, Shuang, Y. F. Liang, Xiaoli Shan, et al.. (2023). Stachydrine Hydrochloride Regulates the NOX2-ROS-Signaling Axis in Pressure-Overload-Induced Heart Failure. International Journal of Molecular Sciences. 24(18). 14369–14369. 9 indexed citations
7.
Liang, Y. F., L. Xia, Shuang Lu, et al.. (2023). A new mechanism of therapeutic effect of stachydrine on heart failure by inhibiting myocardial ferroptosis. European Journal of Pharmacology. 954. 175881–175881. 19 indexed citations
8.
Chen, Yuwen, Peipei Cheng, Jingzhi Chen, et al.. (2023). Integrin αV mediated activation of myofibroblast via mechanoparacrine of transforming growth factor β1 in promoting fibrous scar formation after myocardial infarction. Biochemical and Biophysical Research Communications. 692. 149360–149360. 3 indexed citations
9.
Zhao, Wenxia, Xiaoli Shan, Xueqin Li, et al.. (2023). Icariin inhibits hypertrophy by regulation of GPER1 and CaMKII/HDAC4/MEF2C signaling crosstalk in ovariectomized mice. Chemico-Biological Interactions. 384. 110728–110728. 2 indexed citations
10.
11.
Tian, Jing, Sining Wang, Xiaoli Shan, et al.. (2022). Trans-cinnamaldehyde protects against phenylephrine-induced cardiomyocyte hypertrophy through the CaMKII/ERK pathway. BMC Complementary Medicine and Therapies. 22(1). 115–115. 5 indexed citations
12.
Wang, Sining, Sai Wang, Xiaoli Shan, et al.. (2022). Stachytine Hydrochloride Improves Cardiac Function in Mice with ISO-Induced Heart Failure by Inhibiting the α-1,6-Fucosylation on N-Glycosylation of β1AR. Frontiers in Pharmacology. 12. 11 indexed citations
13.
Tian, Jing, Xiaoli Shan, Huihua Chen, et al.. (2021). Trans-cinnamaldehyde suppresses microtubule detyrosination and alleviates cardiac hypertrophy. European Journal of Pharmacology. 914. 174687–174687. 8 indexed citations
14.
Li, Weiwei, Jing Tian, Xiaoli Shan, et al.. (2021). Ophiopogonin D alleviates diabetic myocardial injuries by regulating mitochondrial dynamics. Journal of Ethnopharmacology. 271. 113853–113853. 43 indexed citations
15.
Zheng, Jiali, Jing Tian, Sining Wang, et al.. (2020). Stachydrine hydrochloride suppresses phenylephrine-induced pathological cardiac hypertrophy by inhibiting the calcineurin/nuclear factor of activated T-cell signalling pathway. European Journal of Pharmacology. 883. 173386–173386. 16 indexed citations
16.
17.
Chen, Huihua, Tongtong Cao, Jiali Zheng, et al.. (2019). Stachydrine hydrochloride alleviates pressure overload-induced heart failure and calcium mishandling on mice. Journal of Ethnopharmacology. 248. 112306–112306. 23 indexed citations
18.
Liu, Xiao, Xiaoli Shan, Huihua Chen, et al.. (2019). Stachydrine Ameliorates Cardiac Fibrosis Through Inhibition of Angiotensin II/Transformation Growth Factor β1 Fibrogenic Axis. Frontiers in Pharmacology. 10. 538–538. 37 indexed citations
19.
Tian, Jing, Ming Xu, Chen Zhang, et al.. (2018). Shengmai San Alleviates Diabetic Cardiomyopathy Through Improvement of Mitochondrial Lipid Metabolic Disorder. Cellular Physiology and Biochemistry. 50(5). 1726–1739. 33 indexed citations
20.
Zhang, Chen, Xiaoli Shan, Yueling Liao, et al.. (2014). Effects of stachydrine on norepinephrine-induced neonatal rat cardiac myocytes hypertrophy and intracellular calcium transients. BMC Complementary and Alternative Medicine. 14(1). 474–474. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meizhu Wu Breakdown of academic impact, for papers by Ningtian Zhou Breakdown of academic impact, for papers by V. Vijaya Padma Breakdown of academic impact, for papers by Wei‐Yin Wu Breakdown of academic impact, for papers by Hongchen Lin Breakdown of academic impact, for papers by Guoqiang Fu Breakdown of academic impact, for papers by Qiong Lai Breakdown of academic impact, for papers by Mingtai Chen
Rankless by CCL
2026